$15.85
7.58% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US15117B1035
Symbol
CLDX
Sector
Industry

Celldex Therapeutics, Inc. Stock price

$17.15
-2.20 11.37% 1M
-13.69 44.39% 6M
-8.12 32.13% YTD
-23.20 57.50% 1Y
-19.55 53.27% 3Y
+15.42 891.33% 5Y
-379.30 95.67% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.23 1.32%
ISIN
US15117B1035
Symbol
CLDX
Sector
Industry

Key metrics

Market capitalization $1.14b
Enterprise Value $423.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 60.27
P/S ratio (TTM) P/S ratio 162.18
P/B ratio (TTM) P/B ratio 1.52
Revenue growth (TTM) Revenue growth 1.99%
Revenue (TTM) Revenue $7.02m
EBIT (operating result TTM) EBIT $-195.08m
Free Cash Flow (TTM) Free Cash Flow $-159.70m
Cash position $719.18m
EPS (TTM) EPS $-2.45
P/E forward negative
P/S forward 310.35
EV/Sales forward 115.34
Short interest 15.94%
Show more

Is Celldex Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Celldex Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Celldex Therapeutics, Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Celldex Therapeutics, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Celldex Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7.02 7.02
2% 2%
100%
- Direct Costs 3.18 3.18
6% 6%
45%
3.84 3.84
1% 1%
55%
- Selling and Administrative Expenses 35 35
27% 27%
504%
- Research and Development Expense 160 160
39% 39%
2,284%
-192 -192
38% 38%
-2,734%
- Depreciation and Amortization 3.18 3.18
6% 6%
45%
EBIT (Operating Income) EBIT -195 -195
37% 37%
-2,779%
Net Profit -158 -158
12% 12%
-2,249%

In millions USD.

Don't miss a Thing! We will send you all news about Celldex Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celldex Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Neutral
GlobeNewsWire
about one month ago
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing -
Neutral
GlobeNewsWire
about one month ago
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 -
More Celldex Therapeutics, Inc. News

Company Profile

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Head office United States
CEO Anthony Marucci
Employees 186
Founded 1983
Website www.celldex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today